Neither a beta-blocker nor an angiotensin-converting enzyme (ACE) inhibitor, used as prophylaxis against trastuzumab’s (Herceptin) adverse cardiac effects, successfully prevented left ventricle remodelling in breast cancer patients in a randomized trial.
by Michael Smith – North American Correspondent, MedPage Today
